Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 15, 2021 at 01:37 pm IST
Share
Kwang Dong Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was KRW 817.48 million compared to KRW 791.42 million a year ago. Net income was KRW 8,940.88 million compared to KRW 30,515.25 million a year ago. Basic earnings per share from continuing operations was KRW 218 compared to KRW 743 a year ago. Diluted earnings per share from continuing operations was KRW 217 compared to KRW 742 a year ago. Basic earnings per share was KRW 218 compared to KRW 743 a year ago. Diluted earnings per share was KRW 217 compared to KRW 742 a year ago.
For the nine months, sales was KRW 1,810.97 million compared to KRW 2,543.67 million a year ago. Net income was KRW 17,431.9 million compared to KRW 52,159.86 million a year ago. Basic earnings per share from continuing operations was KRW 424 compared to KRW 1,293 a year ago. Diluted earnings per share from continuing operations was KRW 424 compared to KRW 1,293 a year ago. Basic earnings per share was KRW 424 compared to KRW 1,293 a year ago.
Kwangdong Pharmaceutical Co Ltd is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Company operates its business through five segments. The Mineral Water Business segment supplies drinking spring water under Samdasoo brand. The Distribution Business segment distributes health drinks under brand names of Vita500 and Corn Silk Tea. The Pharmacy Business segment provides Chinese prescription cold medicines, hypertension medicines, cerebral apoplexy medicines and health drinks. The Hospital Business segment offers anticancer agents, blood vessel adjuvants, vitamin D injections and others. The Other segment provides products which not covered by Pharmacy, Hospital and Distribution segments.